Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GaIN: Ga-68-DOTATATE PET/CT vs In-111-pentetreotide in GEP-NET
NCT02078843Phase 2Terminated
- Sponsor
- Insel Gruppe
- Start
- Mar 2014
- Primary completion
- Aug 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind, single-arm trial of gallium ga 68 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Insel Gruppe. Primary endpoints: Number of patients correctly identified as having GEP-NET at 6 months and Number of patients correctly identified as not having GEP-NET at 6 months. Started Mar 2014; status: terminated.
02
Drugs
gallium ga 68 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT02078843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078843.